GHRP-6: What the Research Shows About This Growth Hormone Releasing Peptide

What it is

In the 1980s Cyril Bowers and colleagues built a six-amino-acid peptide that made the pituitary release growth hormone through a receptor nobody had identified. They called it GHRP-6. A decade of work on how it acted led to the discovery of that receptor and then of its natural ligand: ghrelin, the hunger hormone. GHRP-6 is, in that sense, the peptide that found ghrelin.

It is the oldest and least refined of its family. GHRP-2 came next, with more growth hormone per dose; ipamorelin later, with the side signals engineered out. GHRP-6 has never been approved for anything.

What it is studied for

Growth hormone release, in single-dose human studies. Appetite, which it stimulates strongly. Heart protection and wound healing, in animals, mostly from a Cuban research program. Nothing about muscle, fat, or recovery has been tested in people.

What the evidence actually shows

In humans

Bowers’ work established that GHRP-6 produces a dose-dependent pulse of growth hormone in healthy adults, and that combining it with GHRH produces a pulse far larger than either alone, the finding behind every GHRH-plus-GHRP stack since (Bowers et al., 1991). At higher doses it also raises cortisol, ACTH, and prolactin for an hour or two, which is what “less selective” means when GHRP-6 is compared with newer peptides (Arvat et al., 1997).

The hunger is the other consistent human finding. Because GHRP-6 activates the same receptor as ghrelin, it produces the same signal, and users describe an appetite that arrives within minutes of a dose.

In animals

Cuban researchers have studied GHRP-6 and related molecules for protecting the heart after injury and for healing wounds, with results in rats and pigs suggesting reduced tissue damage and faster repair (Berlanga-Acosta et al., 2012). It is a real research line and it has not reached human trials.

From user reports

Intense hunger after every dose, which some people use on purpose to eat more during a bulk. Better sleep with a bedtime dose. Water retention, occasional tingling, and slow body-composition changes over a cycle, always alongside training. None of it measured.

How it works

GHRP-6 binds the ghrelin receptor on pituitary cells and in the hypothalamus, triggering a growth hormone pulse and partly lifting somatostatin, the brake that limits it. The same receptor drives hunger, cortisol, and prolactin, and GHRP-6 activates all of them. That is why pairing it with a GHRH-type peptide works so well for growth hormone and why ipamorelin was designed to replace it.

How it is used in studies

Human studies used single doses around 1 microgram per kilogram. Users inject 100 to 200 micrograms under the skin two or three times a day, fasted, often with a GHRH peptide, for 8 to 12 weeks. See the stacks guide and the storage guide.

Side effects and unknowns

Documented: hunger, brief cortisol and prolactin rises, flushing, tiredness. Reported: water retention, tingling in the hands, headaches. The unknowns are the class unknowns, blood sugar and IGF-1 over months and years, plus one specific to GHRP-6: what repeated cortisol bumps several times a day do over time. See the safety guide.

How it compares

• GHRP-2: more growth hormone per dose, somewhat less hunger and cortisol.
• Ipamorelin: similar growth hormone release with almost none of the hunger, cortisol, or prolactin. The reason GHRP-6 is now mostly of historical interest.
• Hexarelin: the strongest pulse and the fastest desensitization.
• MK-677: oral, all-day, with the same hunger and the most human data.
• CJC-1295: GHRH-type, the stacking partner. See the muscle growth guide.

Legal status

Not approved in any country. Sold as a research chemical. WADA bans it in and out of competition.

Bottom line

GHRP-6 is a piece of scientific history that still works exactly as described: a reliable growth hormone pulse with a large side of hunger and a small side of cortisol. If you want the growth hormone without the rest, ipamorelin exists. If you want to eat more, GHRP-6 will see to that.

References

1. Bowers CY, et al. (1991). On the actions of the growth hormone-releasing hexapeptide, GHRP. Endocrinology. PubMed
2. Arvat E, et al. (1997). Preliminary evidence for an interaction between GHRP-6 and the hypothalamic-pituitary-adrenal axis in humans. Endocrinology. PubMed
3. Berlanga-Acosta J, et al. (2012). Growth hormone releasing peptide-6 (GHRP-6) and its therapeutic relevance. Biotecnología Aplicada. PubMed

See also

• Peptide
  GHRP-2: What the Research Shows About This Second-Generation GH Secretagogue

  GHRP-2 is a six-amino-acid peptide that copies ghrelin, the hunger hormone, to make the pituitary release a pulse of growth hormone. Japan approved it as a one-dose diagnostic test; no one has trialed it as a treatment.

• Peptide
  CJC-1295: What the Evidence Says About This GHRH Analog

  CJC-1295 is a longer-lasting version of GHRH, the signal that tells the pituitary to release growth hormone. The DAC form raised GH and IGF-1 for days in one small trial; the no-DAC form (Mod GRF 1-29) has no human trial of its own.

• Peptide
  Hexarelin: What the Research Shows About This Potent GH Secretagogue

  Hexarelin is the most potent growth hormone releasing peptide in human studies, roughly two to three times GHRP-6, with a receptor of its own in heart muscle. Its catch is desensitization: the effect fades within weeks of daily use.